N. Frattarelli

Efficacy of the BEACOPP regimen in refractory and relapsed Hodgkinlymphoma

R. Foà, M. Vignetti, F. Mandelli, 2009, Leukemia & lymphoma.

THE BRAF INHIBITOR VEMURAFENIB PLUS RITUXIMAB PRODUCES A HIGH RATE OF DEEP AND DURABLE RESPONSES IN RELAPSED/REFRACTORY HAIRY CELL LEUKEMIA: UPDATED RESULTS OF A PHASE‐2 TRIAL

R. Foà, B. Falini, G. Gaidano, 2019, Hematological Oncology.

Stage I/II follicular lymphoma: spread of bcl‐2/IgH+ cells in blood and bone marrow from primary site of disease and possibility of clearance after involved field radiotherapy

Emanuela M. Ghia, E. Ghia, R. Foà, 2007, British journal of haematology.

Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia.

R. Foà, B. Falini, G. Gaidano, 2021, The New England journal of medicine.

Conservative treatment for patients over 80 years with acute myelogenous leukemia

F. Mandelli, R. Latagliata, F. Ferrara, 2002, American journal of hematology.

The Chemotherapy-Free Combination of Vemurafenib and Rituximab Produces Deep and Durable Responses in Relapsed or Refractory Hairy Cell Leukemia (HCL) Patients

R. Foà, B. Falini, G. Gaidano, 2017 .